Figure 1. The prevalence of CHIP mutations is higher in patients with obesity.

(A) Prevalence of CHIP mutations across quintiles of BMI and WHR in a cohort of 47,466 unrelated participants in the UK Biobank. The prevalence of CHIP increased with higher WHRs, and the percentage of participants with CHIP was 4.93%, 5.75%, and 6.56% in the lowest, middle, and highest WHR quintiles, respectively. (B–G) Higher frequencies of CHIP mutations in patients with a high BMI (>30 kg/m²) compared with patients with a low BMI (≤25 kg/m²). TCGA data were derived from patients with 1 of the following 6 types of cancer: BLCA, COAD, CESC, READ, SKCM, or UCEC.